Bay 55-9837 TFA , CAS No.463930-25-8, Agonist of PAC 1 receptor;Agonist of VPAC 1 receptor;Agonist of VPAC 2 receptor

Features and benefits
    Item Number
    B288002
    Grouped product items
    SKUSizeAvailabilityPrice Qty
    B288002-1mg
    1mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $345.90
    B288002-5mg
    5mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $1,179.90
    B288002-10mg
    10mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $1,499.90

    Potent and selective VPAC2agonist

    Basic Description

    Product NameBay 55-9837 TFA , CAS No.463930-25-8
    SynonymsUNII-SQD60KZ8RJ | His-ser-asp-ala-val-phe-thr-asp-asn-tyr-thr-arg-leu-arg-lys-gln-val-ala-ala-lys-lys-tyr-leu-gln-ser-ile-lys-asp-lys-arg-tyr-NH2 | BAY-55-9837 | AKOS024457254 | SQD60KZ8RJ | PD079349
    GradeMoligand™
    Product Description

    Bay 55-9837 TFA is a potent and highly selective agonist of VPAC2. Bay 55-9837 TFA may be a useful therapy for the research of type 2 diabetes.

    Specifications & PurityMoligand™, ≥98%
    Biochemical and Physiological MechanismsSelective VPAC2receptor agonist (EC50values are 0.4, 100 and >1000 nM for VPAC2, VPAC1and PAC1, respectively in a cAMP accumulation assay; IC50values are 60, 8700 and >10000 nM for VPAC2, VPAC1and PAC1, respectively in a competition binding assay). Stimul
    SequenceHSDAVFTDNYTRLRKQVAAKKYLQSIKNKRY(Modifications: Tyr-31 = C-terminal amide)
    Action TypeAGONIST
    Mechanism of actionAgonist of PAC 1 receptor;Agonist of VPAC 1 receptor;Agonist of VPAC 2 receptor

    Associated Targets(Human)

    VIPR2 Tchem Vasoactive intestinal polypeptide receptor 2 (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    VIPR1 Tchem Vasoactive intestinal polypeptide receptor 1 (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
    ADCYAP1R1 Tchem Pituitary adenylate cyclase-activating polypeptide type I receptor (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

    Product Specifications

    Storage TempStore at -20°C
    Shipped InIce chest + Ice pads
    CAS463930-25-8

    Certificates

    Certificate of Analysis(COA)

    Enter Lot Number to search for COA:

    Find and download the COA for your product by matching the lot number on the packaging.

    6 results found

    Lot NumberCertificate TypeDateItem
    C2408276Certificate of AnalysisJan 23, 2024 B288002
    C2408277Certificate of AnalysisJan 23, 2024 B288002
    C2408278Certificate of AnalysisJan 23, 2024 B288002
    C2408279Certificate of AnalysisJan 23, 2024 B288002
    C2408286Certificate of AnalysisJan 23, 2024 B288002
    C2408287Certificate of AnalysisJan 23, 2024 B288002

    Genetic information

    Alternate NamesUNII-SQD60KZ8RJ | His-ser-asp-ala-val-phe-thr-asp-asn-tyr-thr-arg-leu-arg-lys-gln-val-ala-ala-lys-lys-tyr-leu-gln-ser-ile-lys-asp-lys-arg-tyr-NH2 | BAY-55-9837 | AKOS024457254 | SQD60KZ8RJ | PD079349
    Reference
    • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
    • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
    • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
    • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
    • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
    • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
    • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
    • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
    • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
    • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more

    Related Documents

    Solution Calculators